The financial markets have thoroughly depreciated the stem cell universe but, many struggling stem cell companies are getting second, third and fourth chances Read more…
Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) Read more…
Researchers have shown it is possible to grow properly working joints inside the body using a patient’s own stem cells, after damaged bone has been removed. Read more…
A stem cell therapy for osteoarthritis is to be tested on patients for the 1st time in the UK. Read more…
Cardiologists hope new treatment can prolong the lives of patients with dilated cardiomyopathy (DCM). Read more…
The Vatican on 7/31/10 condemned as “unacceptable” the green light given by the FDA to a clinical trial for a treatment based on human embryonic stem cells. Read more…
After a big rally in July, investors could be in for another bout of economic jitters this week as the focus shifts from earnings to the weak job market. Read more…
NBS has been awarded a $700 K contract for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.